Barinthus Biotherapeutics (BRNS) Accounts Payables (2020 - 2026)

Barinthus Biotherapeutics has reported Accounts Payables for 7 years, with the latest figure at $993000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 26.82% year-over-year to $993000.0; the trailing twelve-month figure through Mar 2026 stood at $993000.0 (down 26.82% YoY), and the FY2025 full-year result was $350000.0, down 85.85% from the prior year.
• Accounts Payables for Q1 2026 stood at $993000.0, up from $350000.0 in the prior quarter.
• The five-year high for Accounts Payables was $5.1 million in Q3 2023, with the low at $350000.0 in Q4 2025.
• Historically, Accounts Payables has averaged $2.5 million across 5 years, with a median of $2.4 million in 2023.
• Annual changes were most pronounced in 2023 — Accounts Payables jumped 113.4% — and 2025, when it tumbled 85.85%.
• Barinthus Biotherapeutics' Accounts Payables stood at $3.7 million in 2022, then slumped by 57.28% to $1.6 million in 2023, then jumped by 54.53% to $2.5 million in 2024, then plunged by 85.85% to $350000.0 in 2025, then surged by 183.71% to $993000.0 in 2026.
• The last three Accounts Payables figures came in at $993000.0 (Q1 2026), $350000.0 (Q4 2025), and $698000.0 (Q3 2025), per Business Quant data.